1. Real-World Evidence

3. Overview

4. Real-World Data in Oncology

5. Real-World Evidence in Oncology

6. Why Do We Need RWE?

7. RWE vs Clinical Trials

8. PALOMA-2: Demographics and Baseline Characteristics

9. PALOMA-3: ITT Population Clinical Characteristics

10. First-Line CDK4/6 Treatment: Outcomes in Older Women

11. Pooled Retrospective Subgroup Analysis

12. Pooled Efficacy and Safety of CDK4/6 Inhibitors

13. Palbociclib Real-World Insights (IRIS): Real-World Treatment Outcomes in Patients Treated With Palbociclib Combination Therapy

14. Palbociclib in Highly Pre-Treated Patients With ER+/HER2- MBC

15. Real-World Insights: Remarks

16. What Do Phase 4 Trials and Single-Institution Datasets Add to Our Understanding and Clinical Practice?

17. Practical Strategies for Incorporating RWE

18. RWE in the Clinic

19. Clinical Considerations

20. Dose Modifications

21. Further Directions

22. Real-World Clinical Outcomes of Palbociclib in HR+ MBC: Retrospective, Single-Institution Review

23. Real-World Clinical Outcomes of Palbociclib in HR+ MBC: Efficacy and Safety Results

24. Real-World Clinical Outcomes of Palbociclib in HR+ MBC: Investigator Conclusions

25. Everolimus in Postmenopausal HR+ ABC (BOLERO-2): Demographics and Baseline Characteristics

26. BOLERO-2: Safety Profile

27. RWE: Everolimus Use in First-Line HR+ MBC

28. RWE: Everolimus Dosing Patterns

29. RWE for Everolimus in HR+ MBC

30. Everolimus and CDK4/6 Inhibitors: Clinical Questions

31. Alpelisib

32. RWE on Dose Reductions and Delays for CDK4/6 Inhibitors

33. Ongoing Observational/RWE Trials With CDK4/6 Inhibitors

34. Real-World Use of Palbociclib in Patients With HR+/HER2- ABC: Results From POLARIS

35. Ongoing Observational/RWE Trials With CDK4/6 Inhibitors (cont)

36. RWD and RWE: Take-Home Messages and Concluding Remarks

37. Abbreviations

38. Abbreviations (cont)